Adrenaline (Epinephrine) Injectors - Fast Facts

ASCIA has developed this Fast Facts about adrenaline injectors, to summarise key points from the recently updated ASCIA Guidelines for Adrenaline Injector Prescription.  

pdfASCIA PCC Adrenaline Injectors Fast Facts 2023123.75 KB

1. Adrenaline can save lives when used to treat anaphylaxis

ASCIA recommends adrenaline as the first line, emergency treatment for anaphylaxis (severe allergic reactions), using either of the two adrenaline injector brands listed below, which are:

  • TGA approved and available on the PBS in Australia (EpiPen® is Pharmac listed in New Zealand from 1 February 2023).
  • Widely used in other countries.


Supplier: Allergy Concepts


Supplier: Viatris

 Anapen devices  EpiPen devices

Doses recommended by ASCIA

  • Anapen® 150 (Jr): Children 7.5-20 kg (~1-5 yr.)
  • Anapen® 300: Adults or children >20kg (>5 yr.)
  • Anapen® 500*: Adults or children >50kg (>12 yr.)

Doses recommended by ASCIA:

  • EpiPen® Junior: Children 7.5-20 kg (~1-5 yr.)
  • EpiPen®: Adults or children >20kg (>5 yr.) 
  • EpiPen®: Adults or children >50kg (>12 yr.) 

*The dose of adrenaline in Anapen 500 is consistent with the intramuscular injection (IMI) adrenaline dose recommendations in several publications for people who weigh >50kg.

2. It is important to know how to use Anapen® and EpiPen® devices

Anapen® (4 steps) and EpiPen® (3 steps) are both injected into the outer mid-thigh, but they have different instructions, which are on the device labels and the ASCIA website

ASCIA Action Plans for Anaphylaxis are available for each brand, or a General Plan with QR Code can be used, which links to instructions for both brands

Instructions for both brands are included in ASCIA Anaphylaxis e-training courses

3. There are many reasons why it is important to have two brands
  • To ensure continued supply of life saving adrenaline, particularly if one brand has stock shortages.
  • To encourage suppliers to provide devices with longer shelf life.
  • To provide a choice of dose, if prescribers prefer a higher dose (500 microgram device) for people >50kg, which may reduce the need for further adrenaline doses in older teens and adults >50kg.
  • To provide choice for consumers to access devices with points of difference to best suit their needs.

© ASCIA 2023

ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand

Content updated January 2023

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia